

1 **Genomic and phylogenetic characterization of Leanyer virus, a novel**  
2 **orthobunyavirus isolated in northern Australia**

3  
4 Nazir Savji<sup>1\*</sup>, Gustavo Palacios<sup>1\*#</sup>, Amelia Travassos da Rosa<sup>2</sup>, Stephen Hutchison<sup>3</sup>,  
5 Christopher Celone<sup>3</sup>, Jeffrey Hui<sup>1&</sup>, Thomas Briese<sup>1</sup>, Charles H. Calisher<sup>4</sup>, Robert B.  
6 Tesh<sup>2#</sup>, W. Ian Lipkin<sup>1</sup>

7  
8 <sup>1</sup>Center for Infection and Immunity, Mailman School of Public Health, Columbia  
9 University, New York, NY, USA

10 <sup>2</sup>Center for Biodefense and Emerging Infectious Diseases, Department of Pathology,  
11 University of Texas Medical Branch, Galveston, TX, USA

12 <sup>3</sup>454 Life Sciences, Branford, CT, USA

13 <sup>4</sup>Arthropod-borne and Infectious Diseases Laboratory, Department of Microbiology,  
14 Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences,  
15 Colorado State University, Fort Collins, CO, USA

16 <sup>&</sup>Present Address: School of Pharmacy and Pharmaceutical Sciences, University of  
17 Buffalo, Buffalo, NY, USA

18 \*Contributed equally

19 **Running title:** Characterization of Leanyer virus

20 **Word Count:** 4,020

21 **Abstract Word Count:** 91

22 **Figures:** 5

23 **Tables:** 3

24 **Supplementary Tables: 3**

25 **Supplementary Figure: 1**

26

27 **Corresponding Authors:**

28 #Gustavo Palacios, PhD

29 Center for Infection and Immunity

30 Mailman School of Public Health, Columbia University

31 722 West 168th Street, Room 1709, New York, New York 10032

32 Voice: (212) 342-9034; Fax: (212) 342-9044; gp2050@columbia.edu

33

34 #Robert B. Tesh, MD

35 Department of Pathology and Center for Biodefense and Emerging Infectious Diseases

36 University of Texas Medical Branch

37 301 University Boulevard, Galveston, TX 77555-0609

38 Voice: (409) 747-2431; rtesh@utmb.edu

39

40 **Summary**

41 Leanyer virus (LEAV), currently classified as a member of the genus *Orthobunyavirus*,  
42 family *Bunyaviridae*, was originally isolated from a pool of *Anopheles meraukensis*  
43 mosquitoes, collected at Leanyer, Northern Territory, Australia in 1974. When it failed to  
44 react in serological tests with antisera from other known viruses, full-length genomic  
45 sequencing was pursued to determine the relationship of LEAV to other orthobunyavirus  
46 species. Genetic and serological characterization confirmed its antigenic distance from  
47 other orthobunyaviruses, including to its closest genetic neighbors, the Simbu group  
48 viruses, suggesting that it may represent a new antigenic complex.

49 **Introduction**

50           The family *Bunyaviridae* constitutes one of the largest taxonomic groupings of  
51 RNA viruses, containing more than 350 viruses. The family *Bunyaviridae* (commonly  
52 known as bunyaviruses) comprises five genera: *Hantavirus*, *Nairovirus*,  
53 *Orthobunyavirus*, *Phlebovirus*, and *Tospovirus*, based on serological and molecular  
54 characteristics (<http://www.ictvonline.org/virusTaxonomy.asp?version=2008>). All  
55 members of the family share certain common characteristics including: (1) a tri-  
56 segmented genome; (2) a negative or ambisense coding strategy; (3) four structural  
57 proteins; (4) cytoplasmic replication; and (5) assembly and maturation at the Golgi  
58 apparatus. Viruses within each genus share similar segment and structural protein  
59 sizes, and nucleotide (nt) sequences at the 3' and 5' termini of each segment.

60           Viruses in the genera *Orthobunyavirus*, *Nairovirus*, *Phlebovirus* and *Tospovirus*  
61 are transmitted by arthropods (mosquitoes, midges, sandflies, ticks or thrips). In  
62 contrast, viruses in the genus *Hantavirus* are not arthropod transmitted, but are  
63 acquired by aerosol exposure to virus-contaminated excreta or by bite of their rodent or  
64 shrew hosts (Nichol *et al.*, 2005; Ramsden *et al.*, 2009). Viruses that impinge on human  
65 health, either directly by causing illness, or indirectly by causing disease and economic  
66 loss in domestic animals or crop plants, are found in each of the five genera (Elliott,  
67 1997; Nichol *et al.*, 2000).

68           The largest genus in the family is the *Orthobunyavirus*, which currently contains  
69 more than 170 viruses, assigned to 48 distinct species based on serological relatedness  
70 by complement fixation test (mediated by the N protein) or hemagglutination-inhibition  
71 and neutralization tests (mediated by glycoproteins) (Nichol *et al.*, 2005). Despite the

72 association of many of the orthobunyaviruses with human and animal disease,  
73 molecular characterizations of the entire genus has been limited to four serologic  
74 groups, namely California Encephalitis, Bunyamwera, Group C, and Simbu (Bowen *et*  
75 *al.*, 1995; Dunn *et al.*, 1994; Nunes *et al.*, 2005b; Saeed *et al.*, 2000). These antigenic  
76 complexes bring together several viruses (e.g. Guaroa, Kairi and Bunyamwera species  
77 are all grouped in the Bunyamwera complex). Because of the paucity of genetic data for  
78 many of the orthobunyaviruses, taxonomic placements must be regarded as fluid, since  
79 antigenic relatedness among segmented viruses may vary depending on the particular  
80 serologic test used or because of natural reassortment among closely related viruses.

81         Leanyer virus (LEAV) was initially believed to be a member of the family  
82 *Togaviridae* based on virion size (Doherty *et al.*, 1977), but was later shown to  
83 morphologically consistent with a bunyavirus (Stuckly & Wright, 1983). Initial analysis of  
84 partial sequences showed LEAV to be divergent compared with other  
85 orthobunyaviruses, making it an interesting target for further characterization. Here we  
86 describe rapid full genome sequencing of LEAV, and provide evidence that it represents  
87 a new orthobunyavirus species in a previously unidentified antigenic complex.

## 88 **Results**

### 89 **Serology**

90 A list of antibodies specific to each viruses' proteins used for serological analysis of  
91 LEAV is given in **Table 1**. In summary, LEAV mouse brain antigen (HA titer 1:640 at pH  
92 5.75-6.0) reacted in HI tests with a hyperimmune mouse LEAV antibody (homologous  
93 titer 1:5120), but it failed to react with antibodies to any of the other viruses shown in  
94 **Table 1**. Furthermore, LEAV antibodies failed to react with Oropouche (OROV), Aino  
95 (AINOV), Akabane (AKAV), Koongol (KOOV), Wongal (WONV), and Tete (TETEV)  
96 virus antigens in CF (**Supplemental Table 1**) and failed to react with OROV and  
97 WONV in HI tests (**Supplemental Table 2**). LEAV antibodies also failed to detect  
98 proteins from AINOV and OROV in western blot (data not shown).

99

### 100 **Sequence acquisition and analysis**

101 Consistent with the genomic organization of orthobunyaviruses (Gentsch *et al.*,  
102 1977; Gentsch & Bishop, 1978; Obijeski *et al.*, 1976a; Obijeski *et al.*, 1976b), the  
103 genome of LEAV comprises three RNA segments: a large (L) segment that encodes a  
104 large (L-) polymerase-related open reading frame (ORF) in the negative sense  
105 orientation (GenBank Accession number HM627178); a medium (M) segment that  
106 encodes the polyprotein (M) in the negative sense orientation (GenBank Accession  
107 number HM627176); and a small (S) segment that encodes a nucleocapsid protein (NP)  
108 and a non-structural protein (NSs), both in the negative sense orientation, but in  
109 different ORFs (GenBank Accession Number HM627177). The results of the  
110 phylogenetic analyses of the L, M, and NP ORFs indicate that LEAV virus is distantly

111 related to members of the Simbu serogroup. It is most closely related with OROV in all  
112 three amino acid trees (**Figure 1A, B, C, respectively**). Nucleotide trees show similar  
113 topology, though interpretation is limited given sequence divergence. (**Supplementary**  
114 **Figure 1**). No evidence for reassortment was detected.

115 LEAV sequences were compared with published orthobunyavirus sequences for  
116 members of Bunyamwera, California encephalitis, Simbu, and Group C complexes to  
117 determine intragroup and intergroup average distances, using strategies accepted for  
118 other virus groups (Collao *et al.*, 2009; Ward *et al.*, 1992). The intragroup and intergroup  
119 p-distances were clearly distinguishable for the polymerase and the nucleoprotein  
120 (**Figure 2A, B, respectively**). Cut offs of 59% and 60% similarity were established,  
121 respectively, at the aa level. However, some overlap was observed in the polyprotein.  
122 The average similarity between LEAV and Simbu viruses was 47.6%  $\pm$  3.5% and 53.7%  
123  $\pm$  3.1% in the polymerase and the nucleoprotein, respectively. Comparison between  
124 LEAV and OROV and AINOV showed 59% and 36.4% similarity in the polymerase and  
125 polyprotein, respectively, with OROV and 30.9% with the AINOV polyprotein. These  
126 values are in the range of similarity values observed between species belonging to  
127 different antigenic groups (**Table 2**).

### 128 ***Open Reading Frames (ORFs)***

129 *Large RNA-dependent RNA polymerase (L)*. The 2260 aa LEAV viral RNA-  
130 dependent RNA polymerase (RdRp; 264 kDa, pI=6.4) is similar in size to other  
131 orthobunyavirus reference strains falling between the 2238 aa Bunyamwera and the  
132 2263 aa LaCrosse virus L proteins. Certain areas overlap conserved regions among all  
133 orthobunyaviruses, suggesting an association with function; region I is located in the

134 amino terminus and is centered on aa P<sub>75</sub>D; region II, also located in the amino  
135 terminus, is centered on aa R<sub>651</sub>Y. Regions I and II have been found to also be  
136 conserved among all bunyaviruses (Muller *et al.*, 1994). Region III (948-1239) is  
137 located in the center of the protein and contains the polymerase motifs that comprise  
138 the polymerase module (A (1045-1062), B (1129-1151), C (1170-1184), D (1214-1225))  
139 found in all RNA-dependent polymerases ranging from the RNA-dependent DNA  
140 polymerase encoded by reteroid elements to the RNA-dependent RNA polymerases  
141 encoded by the positive, negative, and double stranded RNA viruses (Poch *et al.*, 1989;  
142 Xiong & Eickbush, 1990). The pre-A (948-977) and E motifs (1228-1239) identified in  
143 region 3 by Muller *et al.* were also found in LEAV. The fourth conserved region (1240-  
144 1343), identified by Aquino *et al.*, was also conserved in LEAV (**Figure 3**) (Aquino *et al.*,  
145 2003).

146 *Polyprotein (M)*: The 1419 aa LEAV polyprotein (161.8 kDa, pI=8.4) is  
147 cotranslationally cleaved into the 285aa Gn (32.7 kDa, pI=8.9), 947aa Gc (107.9 kDa,  
148 pI=6.7), and 173aa NSm (19.7 kDa, pI=9.2). Stuckely and Wright determined the Gn  
149 and Gc to be 35 and 115 kDa, respectively, both within 10% of our predictions and  
150 similar in size to the Bunyamwera virus (Stuckely & Wright, 1983). When compared with  
151 other orthobunyaviruses reference strains and Aino virus, the M proteins of LEAV are  
152 comparably sized (**Table 3**) (Wang *et al.*, 2001; Yanase *et al.*, 2003).

153 Since the Gn is poorly conserved among bunyaviruses, this is the area of less  
154 conservations of the whole polyprotein. The N-terminal sequence is consistent with a  
155 functional signal peptide for membrane translocation (Blobel & Dobberstein, 1975;  
156 Lingappa *et al.*, 1978; von Heijne, 1988) similar to those of other viruses in the genus

157 (Fazakerley *et al.*, 1988). Cleavage of the signal peptide between aa 14 and 15 with  
158 respect to the first methionine is compatible with conservation of terminal aa tripeptides  
159 (Lees *et al.*, 1986). Prediction of signalase cleavage by SignalP 3.0 between aa 14 and  
160 15 supports this view. The Gn contains the conserved arginine in position 299  
161 suggesting cleavage of the mature Gn from the downstream NSm at the carboxy  
162 terminus of the Gn is likely mediated by an enzyme that has specificity for basic  
163 residues (Fazakerley *et al.*, 1988). There is little conservation near the NSm/Gc  
164 junction, so a potential cleavage site, possibly executed by signalase (Fazakerley *et al.*,  
165 1988), is not obvious. Cleavage after a conserved alanine residue (A<sub>472</sub>) analogous to  
166 the termination of NSm in California serogroup viruses (Campbell & Huang, 1999) is  
167 possible. SignalP predicts cleavage at VVA<sub>472</sub>-EI, which would result in -3=V and -1=A,  
168 one of the most frequent combinations in signalase sites. Although close to a potential  
169 glycosylation site, it is greater than the “minimum glycosylation distance” of 13 aa that  
170 has been determined for cleaved internal signals (Nilsson *et al.*, 1994).

171 Six potential glycosylations sites were identified using NetNGlyc 1.0  
172 (<http://www.cbs.dtu.dk/services>), two in the Gn, one in the NSm and four in the Gc. Two  
173 in the Gn and one in each the NSm, and Gc are unique. The glycosylation site in the  
174 amino terminus of the Gc is conserved among Peaton, Tinaroo, and Akabane viruses  
175 and one in the Gc is conserved among Akabane and Aino viruses. Only one  
176 glycosylation site in the C-terminus of the Gc is conserved with Oropouche. Peaton,  
177 Tinaroo, Akabane, Aino and Oropouche are all Simbu serogroup viruses (**Figure 4**).

178 Prediction of transmembrane regions using the transmembrane hidden Markov  
179 model in the program TopPred2

180 (<http://bioweb.pasteur.fr/seqanal/interfaces/toppred.html>), predicts 8 transmembrane  
181 regions: two in the Gn (200-220, 223-243), three in the NSm (306-326, 357-377, 454-  
182 474), and three in the Gc (956-976, 1046-1066, 1375-1395). The two transmembrane  
183 regions in the Gn together form a very long hydrophobic sequence (200-243), which are  
184 subsequently followed by charged amino acids (244-252) similar to the stop-transfer  
185 sequences seen in the transmembrane domains of other viral envelope proteins (Garoff  
186 *et al.*, 1980; Jou *et al.*, 1980; Rose *et al.*, 1980). The transmembrane region predicted  
187 at position 1375-1395 in the Gc acts as a potential membrane anchor (Fazakerley *et al.*,  
188 1988; Pekosz *et al.*, 1995) (**Figure 4**).

189 The LEAV Gn protein consists of 299 aa with a predicted cytoplasmic tail (CT) of  
190 69 residues. The Gc consists of 961 aa and has a CT of 24 aa. These values are  
191 consistent with predictions of the CT for Bunyamwera virus, the prototype of the genus  
192 *Orthobunyavirus* (Elliott, 1990; Lees *et al.*, 1986).

193 The fusion peptide identified in La Crosse virus (LACV) from aa 1066-1087 is  
194 conserved in LEAV from aa 1043-1064 suggesting that the Gc of LEAV acts as a class  
195 II fusion protein, similar to the E1 fusion peptide of the alphaviruses, Sindbis virus and  
196 Semliki Forest virus (Plassmeyer *et al.*, 2007). None of the six epitopes identified in  
197 California encephalitis group viruses by Cheng *et al.* (Cheng *et al.*, 2000) are conserved  
198 in LEAV. The overall topology of the virus appears to be well conserved, as indicated by  
199 the conservation of 51 cysteines with all other orthobunyaviruses (Grady *et al.*, 1987;  
200 Lees *et al.*, 1986; Pardigon *et al.*, 1988), 14 in the Gn, 8 in the NsM, and 29 in the Gc  
201 (**Figure 4**).

202           *Nucleocapsid (NP) and Non-Structural (NSs) proteins*: The LEAV 235 aa NP  
203 (26.3kDa, pI=8.9) is consistent with Stuckley and Wright's NP of 29 kDa (Stuckly &  
204 Wright, 1983). It shows between 24% (Tete virus) and 60% (Aino virus) conservation at  
205 the aa level and between 40% (Tete virus) and 63% (Aino virus) at the nt level to other  
206 orthobunyaviruses, thus satisfying the minimum 10% divergence requirement of the  
207 ICTV in the NP for a novel species. Interestingly, of the six conserved regions identified  
208 in the Simbu serogroup viruses by Saeed et al.(Saeed *et al.*, 2001), regions two through  
209 six are well conserved with NT 16701, whereas region one is only somewhat  
210 conserved. There are also several individual aa that have been identified as being  
211 globally conserved in the NP among the 4 major serogroups: Buyamwera, California,  
212 Group C, and Simbu. There are 46 positions that are strictly conserved in all 51 viruses  
213 in these four groups, while a further 14 are conserved in at least 45 (90%) of the N  
214 protein sequences (Eifan & Elliott, 2009). These residues are presumably critical for the  
215 N protein function. Of the 60 conserved amino acids, 50 are conserved in LEAV. The  
216 four residues (P<sub>125</sub>, G<sub>131</sub>, Y<sub>158</sub>, I<sub>231</sub>) involved in formation of ribonucleoprotein complexes  
217 (Eifan & Elliott, 2009) are all conserved in LEAV (**Figure 5**). Of the 10 residues  
218 identified as involved in RNA synthesis, 8 are conserved in NT 16701. LEAV encodes a  
219 NSs, as do most other orthobunyaviruses, in a second ORF of the S segment. The 93  
220 aa (10.8kDa, pI=10.8) falls within the range of NSs sizes of 83 to 109 residues (Dunn *et*  
221 *al.*, 1994) and may correspond to the p8 protein identified by Stuckley and Wright  
222 (Stuckly & Wright, 1983). The NSs is poorly conserved when compared to Simbu group  
223 viruses, showing between 28% and 37% similarity at the aa level (55% to 60% at the nt  
224 level).

## 225 **Discussion**

226           According to the ICTV, a virus belongs to a serogroup if it cross-reacts with  
227 members of that group by one or more serological tests (Nichol *et al.*, 2005). Previous  
228 studies of Simbu group viruses have demonstrated extensive cross-reactivity through  
229 complement fixation tests (Kinney & Calisher, 1981). LEAV does not show cross  
230 reactivity with other orthobunyaviruses and phylogenetic analyses of the M and S  
231 segments of LEAV show it to be only distantly related to Simbu serogroup viruses.  
232 Furthermore, p-distance frequency calculations demonstrate that differences in aa  
233 specified by the L and S segments of LEAV and other orthobunyaviruses are consistent  
234 with intergroup distances. Although this investigation is based on the limited number of  
235 viruses tested, genetic and serologic evidence indicate that LEAV represents a new  
236 species in the genus *Orthobunyavirus* and may represent a new antigenic complex.

237           Many other Simbu group viruses have been isolated from sentinel cattle and from  
238 insects in northern Australia, including Aino, Akabane, Douglas, Peaton, and Tinaroo  
239 viruses (Gard *et al.*, 1988). Akabane and Aino viruses have economic and veterinary  
240 importance. Akabane virus causes periodic outbreaks of abortions, stillbirths and  
241 congenital malformations in cattle, sheep and goats in Australia, the Middle East and in  
242 sub-Saharan Africa (Schmaljohn & Nichol, 2007). Aino virus has been associated with  
243 abortions, stillbirths, and congenital defects in cattle, sheep, and goats in Australia and  
244 Japan. As the second closest phylogenetic relative in the M, high relative sequence  
245 similarity in the N, and geographic overlap, Aino virus and LEAV may have evolved from  
246 a similar, but distant, ancestor.

247           Although distantly related, LEAV appears consistently paired with OROV, which  
248 has only been isolated in Central and South America (Pinheiro *et al.*, 2004). OROV is  
249 recognized as an important cause of acute febrile illness, known as Oropouche fever,  
250 among people living in rural and urban communities in tropical South America (Nunes *et*  
251 *al.*, 2005a).

252           Antibodies to LEAV were detected in 9/30 (30%) of cattle initially tested by  
253 (Doherty *et al.*, 1977) in the Northern Territory of Australia. Neutralizing antibodies were  
254 not detected in a limited survey of humans in northern Australia, but were detected in  
255 cattle in Queensland, suggesting a geographical distribution beyond the Northern  
256 Territory (Doherty *et al.*, 1977). Thus, a more extensive survey, with regards to sample  
257 size and geography is necessary to better understand the distribution of this virus and  
258 its role in human, livestock, and wildlife diseases.

259

## 260 **Materials and Methods**

### 261 ***Virus isolation and antigenic characterization***

262           The prototype strain of LEAV (NT 16701) was originally isolated in newborn mice  
263 inoculated intracranially with a clarified homogenate of 100 *Anopheles meraukensis*  
264 mosquitoes collected at Leanyer, Northern Territory Australia in April 1974 (Doherty *et*  
265 *al.*, 1977). It was subsequently reisolated from *Culicoides marksii* at Beatrice Hill, also in  
266 northern Australia (Standfast *et al.*, 1984). Initial characterization of NT 16701 was  
267 done at the Queensland Institute of Medical Research, Brisbane, Qlds., Australia at the  
268 time of isolation. Methods used to prepare antigens for the complement-fixation (CF)  
269 tests and for making immune ascitic fluids have been described previously (Beaty *et al.*,  
270 1989; Travassos da Rosa *et al.*, 1983; Xu *et al.*, 2007). Antigens and antibodies were  
271 both prepared in mice. CF tests were performed by the microtiter technique (Beaty *et*  
272 *al.*, 1989; Xu *et al.*, 2007), using two units of guinea pig complement and overnight  
273 incubation of the antigen and antibody at 4°C. CF titers were recorded as the highest  
274 dilutions giving 3+ or 4+ fixation of complement. Titers of 1:8 were considered positive.  
275 Hemagglutination inhibition (HI) testing was done in microtiter plates as described  
276 previously (Travassos da Rosa *et al.*, 1983). HI tests were performed with 4  
277 hemagglutination units of virus at the optimal pH (5.75) against serial two-fold antiserum  
278 dilutions starting at 1:20. HI titers of 1:20 were considered positive.

279 By complement fixation (CF), hemagglutination-inhibition (HI) and mouse neutralization  
280 tests, NT 16701 was found to be antigenically distinct from 40 suspected arboviruses  
281 known from Australia and New Guinea at that time (Doherty, 1977; Doherty *et al.*,  
282 1977). Based on these initial studies, NT 16701 was designated as a new virus, and

283 named “Leanyer virus” (LEAV). Negative contrast electron microscopy of LEAV-infected  
284 mouse brain showed poorly defined spherical 50 nm diameter particles with dense  
285 cores (Doherty *et al.*, 1977). It was later discovered that LEAV virions were  
286 approximately 110nm in diameter, a size consistent with other bunyaviruses (Stuckly &  
287 Wright, 1983). A limited survey done by neutralization test with sera from humans and  
288 other vertebrates from Australia revealed neutralizing antibodies to LEAV in cattle,  
289 wallabies and dogs but not in humans (Doherty *et al.*, 1977). Additional HI tests were  
290 done at the University of Texas Medical Branch, Galveston with other  
291 orthobunyaviruses and ungrouped bunyaviruses, including Oropouche and Akabane  
292 **(Table 1)**.

293

#### 294 ***Genome sequencing***

295 LEAV was extracted using TRIzol LS (Invitrogen, Carlsbad, CA, USA). Total  
296 RNA extracts were treated with DNase I (DNA-Free, Ambion, Austin, TX, USA) and  
297 cDNA was generated using the Superscript II system (Invitrogen) using random  
298 hexamers that were linked to an arbitrary 17-mer primer sequence (Palacios *et al.*,  
299 2007). Resulting cDNA was treated with RNase H and then amplified by random PCR  
300 (Palacios *et al.*, 2007). Products greater than 70 base pairs (bp) were selected by  
301 column purification (MinElute, Qiagen, Hilden, Germany) and ligated to specific  
302 adapters for sequencing on the 454 Genome Sequencer FLX (454 Life Sciences,  
303 Branford, CT, USA) without fragmentation of the cDNA (Cox-Foster *et al.*, 2007;  
304 Margulies *et al.*, 2005; Palacios *et al.*, 2008). Software programs accessible through the  
305 analysis applications at the GreenePortal website

306 (<http://tako.cpmc.columbia.edu/Tools/>) were used for removal of primer sequences,  
307 redundancy filtering, and sequence assembly. Primers were designed using  
308 pyrosequencing data to fill gaps in the sequence (**Supplemental Table 3**).  
309 Conventional PCRs were performed with BIO-X-ACT polymerase (Bioline, Taunton,  
310 MA, USA) on PTC-200 thermocyclers (Bio-Rad, Hercules, CA, USA): an enzyme  
311 activation step of 5 min at 95 °C was followed by 45 cycles of denaturation at 95°C for 1  
312 min, annealing at 55 °C for 1 min, and extension at 68°C for 1 to 3 min depending on  
313 the expected amplicon size. PCR products were run on 1% agarose gels, gel extracted  
314 and purified (MiniElute, Qiagen), and directly sequenced in both directions with ABI  
315 PRISM Big Dye Terminator 1.1 Cycle Sequencing kits on ABI PRISM 3700 DNA  
316 Analyzers (Perkin-Elmer Applied Biosystems, Foster City, CA). Terminal sequences  
317 were generated using a universal orthobunyavirus primer, targeting the conserved viral  
318 termini (5'- AGT AGT GTR CTC CAC-3'). Sequences of the genomes were verified by  
319 classical Sanger sequencing using primers designed to create amplicons of ~1000 bp  
320 with 500 bp overlap. The assembled data revealed a classical orthobunyavirus genome  
321 (GenBank Accession numbers HM627176, HM627177, and HM627178).

322

### 323 ***Phylogenetic analysis***

324 A set of orthobunyavirus sequences (151 for the L segment; 243 for the  
325 polyprotein M segment and 502 for the nucleocapsid gene) comprising all sequences  
326 from GenBank were used to determine the phylogenic history of LEAV strain NT 16701.  
327 All orthobunyavirus sequences were aligned using the CLUSTAL algorithm (as  
328 implemented in the MEGA package Version 4) at the amino acid (aa) level, with

329 additional manual editing to ensure the highest possible quality of the alignment.  
330 UPGMA analysis at the amino acid level was performed due to the observed high  
331 variability of the underlying nt sequences. Nucleotide phylogenetic trees were also  
332 investigated using the Neighbor-joining algorithm and the kimura 2-parameter model.  
333 The statistical significance of the tree topology was evaluated by bootstrap re-sampling  
334 of the sequences 1000 times. Phylogenetic analyses were performed by using MEGA  
335 software (Kumar *et al.*, 2004).

336

### 337 **Sequence Analysis**

338 Geneious 4.7.5 (Biomatters Inc., Auckland, New Zealand) was used for sequence  
339 assembly and analysis. Topology and targeting predictions were generated by  
340 employing SignalP, NetNGlyc, TMHMM (<http://www.cbs.dtu.dk/services>), the web-  
341 based version of TopPred2 (<http://bioweb.pasteur.fr/seqanal/interfaces/toppred.html>),  
342 and integrated predictions in Geneious (Bendtsen *et al.*, 2004; Claros & von Heijne,  
343 1994; Kahsay *et al.*, 2005; Kall *et al.*, 2004; Krogh *et al.*, 2001).

344

### 345 **Pairwise Sequence Analysis**

346 To establish a potential cutoff for classification of LEAV, we used pairwise  
347 sequence comparison to compare its sequences with all published orthobunyavirus  
348 sequences. Calculations were performed using MEGA software (Kumar *et al.*, 2004) to  
349 calculate the p-distance of the S segment, which is used by the International Committee  
350 for Taxonomy of Viruses (ICTV) for demarcation of species, at both the nt and aa level

351 using pairwise deletion. Calculations were performed using MEGA software (Kumar *et*  
352 *al.*, 2004) to calculate the p-distance of each segment at the nt level.

353

354 **Acknowledgements**

355 This work was supported by Google.org, National Institutes of Health award AI57158  
356 (Northeast Biodefense Center - Lipkin), and USAID Predict funding source code 07-  
357 301-7119-52258 (Center for Infection and Immunity), and the Department of Defense.  
358 Robert Tesh and Amelia Travassos da Rosa were supported by NIH contracts NO1-  
359 AI25489 and HHSN272201000040I.

360

361 **References**

- 362 **Aquino, V. H., Moreli, M. L. & Moraes Figueiredo, L. T. (2003).** Analysis of oropouche virus  
363 L protein amino acid sequence showed the presence of an additional conserved region  
364 that could harbour an important role for the polymerase activity. *Arch Virol* **148**, 19-28.
- 365 **Beaty, B. J., Calisher, C. H. & Shope, R. E. (1989).** Arboviruses. In *Diagnostic Procedures for*  
366 *Viral, Rickettsial and Chlamydial Infections*, pp. 797-855. Edited by N. J. Schmidt & R.  
367 W. Emmons. Washington, DC: American Public Health Association.
- 368 **Bendtsen, J. D., Nielsen, H., von Heijne, G. & Brunak, S. (2004).** Improved prediction of  
369 signal peptides: SignalP 3.0. *J Mol Biol* **340**, 783-795.
- 370 **Blobel, G. & Dobberstein, B. (1975).** Transfer of proteins across membranes. II. Reconstitution  
371 of functional rough microsomes from heterologous components. *J Cell Biol* **67**, 852-862.
- 372 **Bowen, M. D., Jackson, A. O., Bruns, T. D., Hacker, D. L. & Hardy, J. L. (1995).**  
373 Determination and comparative analysis of the small RNA genomic sequences of  
374 California encephalitis, Jamestown Canyon, Jerry Slough, Melao, Keystone and  
375 Trivittatus viruses (Bunyaviridae, genus Bunyavirus, California serogroup). *J Gen Virol*  
376 **76 ( Pt 3)**, 559-572.
- 377 **Campbell, W. P. & Huang, C. (1999).** Sequence comparisons of medium RNA segment among  
378 15 California serogroup viruses. *Virus Res* **61**, 137-144.
- 379 **Cheng, L. L., Schultz, K. T., Yuill, T. M. & Israel, B. A. (2000).** Identification and  
380 localization of conserved antigenic epitopes on the G2 proteins of California serogroup  
381 Bunyaviruses. *Viral Immunol* **13**, 201-213.
- 382 **Claros, M. G. & von Heijne, G. (1994).** TopPred II: an improved software for membrane  
383 protein structure predictions. *Comput Appl Biosci* **10**, 685-686.

384 **Collao, X., Palacios, G., Sanbonmatsu-Gamez, S., Perez-Ruiz, M., Negredo, A. I., Navarro-**  
385 **Mari, J. M., Grandadam, M., Aransay, A. M., Lipkin, W. I., Tenorio, A. & Sanchez-**  
386 **Seco, M. P. (2009).** Genetic diversity of Toscana virus. *Emerg Infect Dis* **15**, 574-577.

387 **Cox-Foster, D. L., Conlan, S., Holmes, E. C., Palacios, G., Evans, J. D., Moran, N. A.,**  
388 **Quan, P. L., Briese, T., Hornig, M., Geiser, D. M., Martinson, V., vanEngelsdorp,**  
389 **D., Kalkstein, A. L., Drysdale, A., Hui, J., Zhai, J., Cui, L., Hutchison, S. K., Simons,**  
390 **J. F., Egholm, M., Pettis, J. S. & Lipkin, W. I. (2007).** A metagenomic survey of  
391 microbes in honey bee colony collapse disorder. *Science* **318**, 283-287.

392 **Doherty, R. L. (1977).** Arthropod-borne viruses in Australia, 1973-1976. *Aust J Exp Biol Med*  
393 *Sci* **55**, 103-130.

394 **Doherty, R. L., Carley, J. G., Filippich, C., Kay, B. H., Gorman, B. M. & Rajapaksa, N.**  
395 **(1977).** Isolation of Sindbis (alphavirus) and Leanyer viruses from mosquitoes collected  
396 in the Northern Territory of Australia, 1974. *Aust J Exp Biol Med Sci* **55**, 485-489.

397 **Dunn, E. F., Pritlove, D. C. & Elliott, R. M. (1994).** The S RNA genome segments of Batai,  
398 Cache Valley, Guaroa, Kairi, Lumbo, Main Drain and Northway bunyaviruses: sequence  
399 determination and analysis. *J Gen Virol* **75 ( Pt 3)**, 597-608.

400 **Eifan, S. A. & Elliott, R. M. (2009).** Mutational analysis of the Bunyamwera orthobunyavirus  
401 nucleocapsid protein gene. *J Virol*.

402 **Elliott, R. M. (1990).** Molecular biology of the Bunyaviridae. *J Gen Virol* **71 ( Pt 3)**, 501-522.

403 **Elliott, R. M. (1997).** Emerging viruses: the Bunyaviridae. *Mol Med* **3**, 572-577.

404 **Fazakerley, J. K., Gonzalez-Scarano, F., Strickler, J., Dietzschold, B., Karush, F. &**  
405 **Nathanson, N. (1988).** Organization of the middle RNA segment of snowshoe hare  
406 Bunyavirus. *Virology* **167**, 422-432.

407 **Gard, G. P., Shorthose, J. E., Weir, R. P., Walsh, S. J. & Melville, L. F. (1988).** Arboviruses  
408 recovered from sentinel livestock in northern Australia. *Vet Microbiol* **18**, 109-118.

409 **Garoff, H., Frischauf, A. M., Simons, K., Lehrach, H. & Delius, H. (1980).** Nucleotide  
410 sequence of cDNA coding for Semliki Forest virus membrane glycoproteins. *Nature* **288**,  
411 236-241.

412 **Gentsch, J., Wynne, L. R., Clewley, J. P., Shope, R. E. & Bishop, D. H. (1977).** Formation of  
413 recombinants between snowshoe hare and La Crosse bunyaviruses. *J Virol* **24**, 893-902.

414 **Gentsch, J. R. & Bishop, D. H. (1978).** Small viral RNA segment of bunyaviruses codes for  
415 viral nucleocapsid protein. *J Virol* **28**, 417-419.

416 **Grady, L. J., Sanders, M. L. & Campbell, W. P. (1987).** The sequence of the mRNA of an  
417 isolate of La Crosse virus. *J Gen Virol* **68 ( Pt 12)**, 3057-3071.

418 **Jou, W. M., Verhoeven, M., Devos, R., Saman, E., Fang, R., Huylebroeck, D., Fiers, W.,  
419 Threlfall, G., Barber, C., Carey, N. & Emtage, S. (1980).** Complete structure of the  
420 hemagglutinin gene from the human influenza A/Victoria/3/75 (H3N2) strain as  
421 determined from cloned DNA. *Cell* **19**, 683-696.

422 **Kahsay, R. Y., Gao, G. & Liao, L. (2005).** An improved hidden Markov model for  
423 transmembrane protein detection and topology prediction and its applications to complete  
424 genomes. *Bioinformatics* **21**, 1853-1858.

425 **Kall, L., Krogh, A. & Sonnhammer, E. L. (2004).** A combined transmembrane topology and  
426 signal peptide prediction method. *J Mol Biol* **338**, 1027-1036.

427 **Kinney, R. M. & Calisher, C. H. (1981).** Antigenic relationships among Simbu serogroup  
428 (Bunyaviridae) viruses. *Am J Trop Med Hyg* **30**, 1307-1318.

429 **Krogh, A., Larsson, B., von Heijne, G. & Sonnhammer, E. L. (2001).** Predicting  
430 transmembrane protein topology with a hidden Markov model: application to complete  
431 genomes. *J Mol Biol* **305**, 567-580.

432 **Kumar, S., Tamura, K. & Nei, M. (2004).** MEGA3: Integrated software for Molecular  
433 Evolutionary Genetics Analysis and sequence alignment. *Brief Bioinform* **5**, 150-163.

434 **Lees, J. F., Pringle, C. R. & Elliott, R. M. (1986).** Nucleotide sequence of the Bunyamwera  
435 virus M RNA segment: conservation of structural features in the Bunyavirus glycoprotein  
436 gene product. *Virology* **148**, 1-14.

437 **Lingappa, V. R., Katz, F. N., Lodish, H. F. & Blobel, G. (1978).** A signal sequence for the  
438 insertion of a transmembrane glycoprotein. Similarities to the signals of secretory  
439 proteins in primary structure and function. *J Biol Chem* **253**, 8667-8670.

440 **Margulies, M., Egholm, M., Altman, W. E., Attiya, S., Bader, J. S., Bembien, L. A., Berka,**  
441 **J., Braverman, M. S., Chen, Y. J., Chen, Z., Dewell, S. B., Du, L., Fierro, J. M.,**  
442 **Gomes, X. V., Godwin, B. C., He, W., Helgesen, S., Ho, C. H., Irzyk, G. P., Jando, S.**  
443 **C., Alenquer, M. L., Jarvie, T. P., Jirage, K. B., Kim, J. B., Knight, J. R., Lanza, J.**  
444 **R., Leamon, J. H., Lefkowitz, S. M., Lei, M., Li, J., Lohman, K. L., Lu, H.,**  
445 **Makhijani, V. B., McDade, K. E., McKenna, M. P., Myers, E. W., Nickerson, E.,**  
446 **Nobile, J. R., Plant, R., Puc, B. P., Ronan, M. T., Roth, G. T., Sarkis, G. J., Simons,**  
447 **J. F., Simpson, J. W., Srinivasan, M., Tartaro, K. R., Tomasz, A., Vogt, K. A.,**  
448 **Volkmer, G. A., Wang, S. H., Wang, Y., Weiner, M. P., Yu, P., Begley, R. F. &**  
449 **Rothberg, J. M. (2005).** Genome sequencing in microfabricated high-density picolitre  
450 reactors. *Nature* **437**, 376-380.

451 **Muller, R., Poch, O., Delarue, M., Bishop, D. H. & Bouloy, M. (1994).** Rift Valley fever virus  
452 L segment: correction of the sequence and possible functional role of newly identified  
453 regions conserved in RNA-dependent polymerases. *J Gen Virol* **75 ( Pt 6)**, 1345-1352.

454 **Nichol, S. T., Arikawa, J. & Kawaoka, Y. (2000).** Emerging viral diseases. *Proc Natl Acad Sci*  
455 *U S A* **97**, 12411-12412.

456 **Nichol, S. T., Beaty, B. J., Elliott, R. M., Goldbach, R., Plyusnin, A., Schmaljohn, C. S. &**  
457 **Tesh, R. B. (2005).** *Virus Taxonomy: Eighth Report of the International Committee on*  
458 *Taxonomy of Viruses*. San Diego, CA: Elsevier Academic Press.

459 **Nilsson, I., Whitley, P. & von Heijne, G. (1994).** The COOH-terminal ends of internal signal  
460 and signal-anchor sequences are positioned differently in the ER translocase. *J Cell Biol*  
461 **126**, 1127-1132.

462 **Nunes, M. R., Martins, L. C., Rodrigues, S. G., Chiang, J. O., Azevedo Rdo, S., da Rosa, A.**  
463 **P. & Vasconcelos, P. F. (2005a).** Oropouche virus isolation, southeast Brazil. *Emerg*  
464 *Infect Dis* **11**, 1610-1613.

465 **Nunes, M. R., Travassos da Rosa, A. P., Weaver, S. C., Tesh, R. B. & Vasconcelos, P. F.**  
466 **(2005b).** Molecular epidemiology of group C viruses (Bunyaviridae, Orthobunyavirus)  
467 isolated in the Americas. *J Virol* **79**, 10561-10570.

468 **Obijeski, J. F., Bishop, D. H., Murphy, F. A. & Palmer, E. L. (1976a).** Structural proteins of  
469 La Crosse virus. *J Virol* **19**, 985-997.

470 **Obijeski, J. F., Bishop, D. H., Palmer, E. L. & Murphy, F. A. (1976b).** Segmented genome  
471 and nucleocapsid of La Crosse virus. *J Virol* **20**, 664-675.

472 **Palacios, G., Druce, J., Du, L., Tran, T., Birch, C., Briese, T., Conlan, S., Quan, P. L., Hui,**  
473 **J., Marshall, J., Simons, J. F., Egholm, M., Paddock, C. D., Shieh, W. J., Goldsmith,**

474 **C. S., Zaki, S. R., Catton, M. & Lipkin, W. I. (2008).** A new arenavirus in a cluster of  
475 fatal transplant-associated diseases. *N Engl J Med* **358**, 991-998.

476 **Palacios, G., Quan, P. L., Jabado, O. J., Conlan, S., Hirschberg, D. L., Liu, Y., Zhai, J.,**  
477 **Renwick, N., Hui, J., Hegyi, H., Grolla, A., Strong, J. E., Towner, J. S., Geisbert, T.**  
478 **W., Jahrling, P. B., Buchen-Osmond, C., Ellerbrok, H., Sanchez-Seco, M. P.,**  
479 **Lussier, Y., Formenty, P., Nichol, M. S., Feldmann, H., Briese, T. & Lipkin, W. I.**  
480 **(2007).** Panmicrobial oligonucleotide array for diagnosis of infectious diseases. *Emerg*  
481 *Infect Dis* **13**, 73-81.

482 **Pardigon, N., Vialat, P., Gerbaud, S., Girard, M. & Bouloy, M. (1988).** Nucleotide sequence  
483 of the M segment of Germiston virus: comparison of the M gene product of several  
484 bunyaviruses. *Virus Res* **11**, 73-85.

485 **Pekosz, A., Griot, C., Stillmock, K., Nathanson, N. & Gonzalez-Scarano, F. (1995).**  
486 Protection from La Crosse virus encephalitis with recombinant glycoproteins: role of  
487 neutralizing anti-G1 antibodies. *J Virol* **69**, 3475-3481.

488 **Pinheiro, F., Rosas, A. T. d. & Vasconcelos, P. (2004).** Oropouche fever. In *Textbook of*  
489 *pediatric infectious diseases*, 5th edn, pp. 2418-2423. Edited by R. Feigin & e. al.  
490 Philadelphia: Saunders.

491 **Plassmeyer, M. L., Soldan, S. S., Stachelek, K. M., Roth, S. M., Martin-Garcia, J. &**  
492 **Gonzalez-Scarano, F. (2007).** Mutagenesis of the La Crosse Virus glycoprotein supports  
493 a role for Gc (1066-1087) as the fusion peptide. *Virology* **358**, 273-282.

494 **Poch, O., Sauvaget, I., Delarue, M. & Tordo, N. (1989).** Identification of four conserved  
495 motifs among the RNA-dependent polymerase encoding elements. *EMBO J* **8**, 3867-  
496 3874.

497 **Ramsden, C., Holmes, E. C. & Charleston, M. A. (2009).** Hantavirus evolution in relation to  
498 its rodent and insectivore hosts: no evidence for codivergence. *Mol Biol Evol* **26**, 143-  
499 153.

500 **Rose, J. K., Welch, W. J., Sefton, B. M., Esch, F. S. & Ling, N. C. (1980).** Vesicular  
501 stomatitis virus glycoprotein is anchored in the viral membrane by a hydrophobic domain  
502 near the COOH terminus. *Proc Natl Acad Sci U S A* **77**, 3884-3888.

503 **Saeed, M. F., Li, L., Wang, H., Weaver, S. C. & Barrett, A. D. (2001).** Phylogeny of the  
504 Simbu serogroup of the genus Bunyavirus. *J Gen Virol* **82**, 2173-2181.

505 **Saeed, M. F., Wang, H., Nunes, M., Vasconcelos, P. F., Weaver, S. C., Shope, R. E., Watts,  
506 D. M., Tesh, R. B. & Barrett, A. D. (2000).** Nucleotide sequences and phylogeny of the  
507 nucleocapsid gene of Oropouche virus. *J Gen Virol* **81**, 743-748.

508 **Schmaljohn, C. S. & Nichol, S. T. (2007).** *Bunyaviridae*. In *Fields Virology*, 5 edn, pp. 1741-  
509 1789. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Wolters Kluwer/Lippincott  
510 Williams & Wilkins.

511 **Standfast, H. A., Dyce, A. L., St George, T. D., Muller, M. J., Doherty, R. L., Carley, J. G.  
512 & Filippich, C. (1984).** Isolation of arboviruses from insects collected at Beatrice Hill,  
513 Northern Territory of Australia, 1974-1976. *Aust J Biol Sci* **37**, 351-366.

514 **Stuckly, K. G. & Wright, P. J. (1983).** Characterization of Leanyer virus: resemblance to  
515 Bunyavirus. *Aust J Exp Biol Med Sci* **61 (Pt 2)**, 193-200.

516 **Travassos da Rosa, A. P., Tesh, R. B., Pinheiro, F. P., Travassos da Rosa, J. F. & Peterson,  
517 N. E. (1983).** Characterization of eight new phlebotomus fever serogroup arboviruses  
518 (Bunyaviridae: Phlebovirus) from the Amazon region of Brazil. *Am J Trop Med Hyg* **32**,  
519 1164-1171.

520 **von Heijne, G. (1988).** Transcending the impenetrable: how proteins come to terms with  
521 membranes. *Biochim Biophys Acta* **947**, 307-333.

522 **Wang, H., Beasley, D. W., Li, L., Holbrook, M. R. & Barrett, A. D. (2001).** Nucleotide  
523 sequence and deduced amino acid sequence of the medium RNA segment of Oropouche,  
524 a Simbu serogroup virus: comparison with the middle RNA of Bunyamwera and  
525 California serogroup viruses. *Virus Res* **73**, 153-162.

526 **Ward, C. W., McKern, N. M., Frenkel, M. J. & Shukla, D. D. (1992).** Sequence data as the  
527 major criterion for potyvirus classification. *Arch Virol Suppl* **5**, 283-297.

528 **Xiong, Y. & Eickbush, T. H. (1990).** Origin and evolution of retroelements based upon their  
529 reverse transcriptase sequences. *EMBO J* **9**, 3353-3362.

530 **Xu, F., Liu, D., Nunes, M. R., AP, D. A. R., Tesh, R. B. & Xiao, S. Y. (2007).** Antigenic and  
531 genetic relationships among Rift Valley fever virus and other selected members of the  
532 genus Phlebovirus (Bunyaviridae). *Am J Trop Med Hyg* **76**, 1194-1200.

533 **Yanase, T., Yoshida, K., Ohashi, S., Kato, T. & Tsuda, T. (2003).** Sequence analysis of the  
534 medium RNA segment of three Simbu serogroup viruses, Akabane, Aino, and Peaton  
535 viruses. *Virus Res* **93**, 63-69.

536

537

538 **Table 1.** Antisera tested by serology (HI and/or NT) against Leanyer virus at the Queensland Institute of Medical  
 539 Research and University of Texas Medical Branch.

540

<b><i>Alphavirus</i></b>	<b><i>Flavivirus</i></b>	<b><i>Bunyaviridae</i></b>	<b><i>Orthobunyavirus</i></b>	<b><i>Orbivirus</i></b>
Getah	Alfuy	Belmont	Aino	Corriparta
Ross River	Edge Hill	Gan Gan	Akabane	D'Aguillar
Sindbis	Kokobera	Kowanyama	Facey's Paddock (Ch 16129)	Eubenangee
Murweh (Ch 16313)	Kunjin	Maprik	Koongol	Mitchell River
	Murray Valley encephalitis	Mapputta	Oropouche	Mudjinbarry
	Saumarez Reef	Trubanaman	Peaton	Nugget
	Stratford		Tete	Tilligerry
			Wongal	Wallal
			Yacaaba	Warrego
				Wongorr
<b><i>Orthomyxovirus</i></b>	<b><i>Rhabdoviridae</i></b>	<b><i>Lyssavirus</i></b>	<b><i>Nairovirus</i></b>	
Dhori	Alpimwar	Bovine Ephemeral fever	Kao Shuan	
Johnston Atoll	Charleville		Taggert	
Upolu	Ngaingan			

541 **Table 2.** Nucleotide (and amino acid) sequence differences between LEAV and  
 542 viruses of recognized orthobunyavirus serogroups.

<b>Comparison</b>	<b>L Segment</b>	<b>M Segment</b>	<b>S Segment</b>
Within Simbu	13.0 ± 0.6 (9.3 ± 0.8)	21.0 ± 0.3 (20.7 ± 0.4)	16.9 ± 0.7 (15.0 ± 1.2)
Within Bunyamwera	24.1 ± 1.1 (17.0 ± 1.7)	31.4 ± 0.8 (30.2 ± 1.5)	22.9 ± 0.9 (20.8 ± 1.3)
Within Group C	N/A	26.0 ± 1.6 (22.6 ± 2.6)	16.4 ± 0.9 (9.3 ± 1.2)
Within California encephalitis	16.9 ± 1.3 (10.9 ± 1.7)	22.3 ± 0.9 (16.9 ± 1.4)	14.7 ± 0.7 (10.8 ± 1.2)
Between LEAV and Bunyamwera	50.5 ± 1.3 (61.8 ± 3.0)	50.0 ± 1.2 (64.1 ± 2.4)	49.6 ± 1.6 (59.1 ± 2.9)
Between LEAV and California encephalitis	46.6 ± 1.7 (57.2 ± 3.4)	50.5 ± 1.8 (61.7 ± 3.4)	46.0 ± 1.6 (58.2 ± 3.0)
Between LEAV and Group C	N/A	47.2 ± 2.4 (60.0 ± 4.1)	50.0 ± 1.7 (61.4 ± 3.0)
Between LEAV and Simbu	45.3 ± 1.8 (52.4 ± 3.5)	54.1 ± 0.6 (67.8 ± 1.2)	40.8 ± 1.5 (46.7 ± 3.1)
Between Bunyamwera and California encephalitis	45.2 ± 1.8 (55.0 ± 3.4)	43.7 ± 1.2 (50.0 ± 2.6)	46.0 ± 1.4 (54.6 ± 2.7)
Between Bunyamwera and Group C	N/A	42.7 ± 1.9 (51.7 ± 3.6)	45.5 ± 1.4 (55.1 ± 2.8)
Between Bunyamwera and Simbu	49.0 ± 1.4 (57.3 ± 3.3)	53.9 ± 0.8 (68.4 ± 1.7)	49.9 ± 1.4 (59.3 ± 2.8)
Between California encephalitis and Group C	N/A	46.0 ± 2.0 (56.5 ± 3.9)	44.8 ± 1.5 (54.8 ± 2.9)
Between California encephalitis and Simbu	48.9 ± 2.0 (55.9 ± 3.8)	55.5 ± 1.2 (69.7 ± 2.3)	47.2 ± 1.4 (57.1 ± 2.8)
Between Group C and Simbu	N/A	46.2 ± 2.0 (54.7 ± 3.7)	45.8 ± 1.4 (56.2 ± 2.9)

543

544

545 **Table 3.** M Segment Protein Sizes.

<b>Virus Name</b>	<b>Gn Size (aa)</b>	<b>NSm Size (aa)</b>	<b>Gc Size (aa)</b>
Leanyer virus	285	173	947
LaCrosse virus	277	173	967
Bunyamwera virus	292	174	955
Oropouche virus	290	175	939
Akabane virus	292	156	936
Aino virus	291	155	941

546

547 **Figure Legends**

548 **Figure 1. Phylogenetic analysis of the A) polymerase, B) polyprotein, C) and**

549 **nucleoprotein.** A set of all complete and partial sequences from GenBank were aligned  
550 using the CLUSTAL algorithm (as implemented in the MEGA package version 3) at the  
551 aa level for the L, M and S segments with additional manual editing to ensure the  
552 highest possible quality of alignment. A set of these sequences representing different  
553 serogroups were used for analysis, with partial sequences removed for correct tree  
554 topology. Neighbor-joining (NJ) analysis at the aa level was performed given the high  
555 observed variability of the nt sequences. Statistical significance of the tree topology was  
556 evaluated by bootstrap re-sampling of the sequences 1000 times. Phylogenetic  
557 analyses were performed using MEGA software (Kumar *et al.*, 2004). Sequence marked  
558 with a black dot represents LEAV.

559 **Figure 2. Pairwise sequence analysis.** The sequence of LEAV was compared with

560 published orthobunyavirus sequences to determine intergroup and intragroup averages  
561 and to classify LEAV. Calculations were performed using p-distance at the aa level. P-  
562 distance values were grouped into three groups: red, distances among different viruses  
563 belonging to the same serogroup (intragroup); green, distances between members of  
564 different viruses belonging to different serogroups; and purple, distance between LEAV  
565 and other viruses in the genus.

566 **Figure 3. Large RNA-dependent RNA polymerase (L) conserved regions.** Simplot

567 analysis identifies regions I-IV with the pre-A, A, B, C, D, and E motifs shown from  
568 region III.

569 **Figure 4. Polyprotein functional regions.** Transmembranes (red arrows),  
570 glycosylation sites (blue arrow), signal peptide (pink), charged amino acids (grey arrow),  
571 and cysteines (purple) are all indicated. The pink cylinder represents the conserved  
572 fusion peptide sequence.

573 **Figure 5. Nucleocapsid.** Conserved amino acids among all orthobunyaviruses which  
574 are also conserved in LEAV are indicated by grey blocks. The orange arrows indicate  
575 regions identified by Saeed et al. as being conserved among all Simbu Group viruses.

576 **Supplementary Figure 1. Phylogenetic analysis of the A) polymerase, B)**  
577 **polyprotein, C) and nucleoprotein.** A set of all complete and partial sequences from  
578 GenBank were aligned using the CLUSTAL algorithm (as implemented in the MEGA  
579 package version 3) at the nt level for the L, M and S segments with additional manual  
580 editing to ensure the highest possible quality of alignment. A set of these sequences  
581 representing different serogroups were used for analysis, with partial sequences  
582 removed for correct tree topology. Neighbor-joining (NJ) analysis at the nt level was  
583 performed given the high observed variability of the nt sequences. Statistical  
584 significance of the tree topology was evaluated by bootstrap re-sampling of the  
585 sequences 1000 times. Phylogenetic analyses were performed using MEGA software  
586 (Kumar *et al.*, 2004). Sequence marked with a black dot represents LEAV.

587

588 **Supplemental Table 1**

Antigens	Complement Fixation test						
	Antibodies						
	Leanyer 5.10.76	Oropouch T-34161	Aino 6.10.69	Akaban T-33756	Koongo 1.26.66	Wonga 4.27.67	Tete 8.18.84
Leanyer T-36190	$\frac{128}{\geq 64}$	0	0*	0	0	0	0
Oropouch 3.19.85	0	$\frac{\geq 64}{\geq \Phi}$	0	$\frac{8}{\geq \Phi}$	0	0	0
Aino 5.8.69	0	0	$\frac{\geq 64}{\geq \Phi}$	$\frac{64}{\geq \Phi}$	0	0	0
Akabane 5.6.69	0	0	$\frac{32}{\geq \Phi}$	$\frac{\geq 64}{\geq \Phi}$	0	0	0
Koongol 1.8.64	0	0	0	0	$\frac{16}{\geq \Phi}$	$\frac{8}{\geq \Phi}$	0
Wongal 5.26.67	0	0	0	0	$\frac{32}{\geq \Phi}$	$\frac{16}{\geq \Phi}$	0
Tete TVP-11869	0	0	0	0	0	0	$\frac{64}{\geq \Phi}$

589 \* &lt;8/&lt;8 Numerator means serum titer and denominator antigen titer

590

591 **Supplemental Table 2**

Antibodies	Hemagglutination Inhibition test		
	Antigens 4u.		
	Leanyer	Oropouche	Wongal
Leanyer	$1:5120$	0	0
Aino	0*	0	0
Akabane	0	0	0
Koongol	0	0	$1:160$
Oropouche	0	$\geq 1:640$	0
Tete	0	1:20?	0
Wongal	0	0	$1:160$

592 \* &lt;1:20

593

594 **Supplemental Table 3.** Primers designed from pyrosequencing data.

595

<b>Name</b>	<b>Sequence</b>
LEAV_L_3776R	TGCAGTCAAAGGAATCTACCAA
LEAV_L_3823R	TCGCTGTTTGAGTAGCTGAAAGTC
LEAV_L_3862R	TAGACAACCAGGCTAAAGATGCAG
LEAV_L_2941R	GATCTGCCCAGGCATCATGT
LEAV_L_4934F	AAATTTGATTTCCCAAAGTGGAA
LEAV_L_4961F	GAAGAGGAGCTCAGAAGGGATGTA
LEAV_L_5028F	AAAAATGTTAGAACGAATTGCAGAAA
LEAV_L_5091F	TTGTTCCAGTTGAAAGAATTAACAAA
LEAV_L_5215F	TGCTGTGCTGTAACAGGGAACTTA
LEAV_M_284F	ACACAGGAACCATCCAAATCACAT
LEAV_M_328R	TGTCCCCATTCTTGAAACTGATG
LEAV_M_854F	CATCTACAGAAGCCTTGAAGACCC
LEAV_M_1022R	CTGTAATTCCCTTTCCTGGAGCA
LEAV_M_2587F	CCAGAACATTTTGCGATG
LEAV_M_2687R	TTGCATTCTAGAAGCCATTTTG
LEAV_M_2936F	AAGGGCTGACACTAACCTTACCTA
LEAV_M_3079R	AGACTTCTGAATGCACCATGTCTA
LEAV_M_3297F	TAGCTTAAGCAGCTATTGCCACAA
LEAV_M_3328R	AGGTCAGGTAGATTGGAGACAGTT
LEAV_M_3794F	GCACAGAAGCAGTGATCTGTACTC
LEAV_M_3903R	CCCTTCAGGGATTTTCATCTGTGT
LEAV_S_452R	GCCATCTCCCATTTGCAGCCCTT
LEAV_S_482R	ACCTGGTGCAAATGCCAAATAGAGAGCA
LEAV_S_500F	AGACTTTGAATTCTATCCTCTTGC
LEAV_S_532F	CAAACATAGTGGAAATGGGCGAC

596

Figure 1

A





Figure 1

B



Figure 2

A



B






Figure 4





Figure 5




Figure 1

C

